• Navin Suthahar, Dongyu Wang, Joseph Pierre Aboumsallem, Canxia Shi, Sanne de Wit, Elizabeth E Liu, Emily S Lau, BakkerStephan J LSJLDivision of Nephrology, Department of Internal Medicine, University of Groningen, Groningen, the Netherlands., Ron T Gansevoort, Bert van der Vegt, Manol Jovani, Bernard E Kreger, Greta Lee Splansky, Emelia J Benjamin, Ramachandran S Vasan, Martin G Larson, Daniel Levy, Jennifer E Ho, and Rudolf A de Boer.
• Department of Cardiology, University of Groningen, Groningen, the Netherlands; Department of Cardiology, Erasmus MC, University Medical Center, Rotterdam, the Netherlands. Electronic address: n.suthahar@erasmusmc.nl.
• Mayo Clin. Proc. 2023 Apr 1; 98 (4): 549558549-558.

ObjectiveTo evaluate the value of serial C-reactive protein (CRP) measurements in predicting the risk of cardiovascular disease (CVD), cancer, and mortality.MethodsThe analysis was performed using data from two prospective, population-based observational cohorts: the Prevention of Renal and Vascular End-Stage Disease (PREVEND) study and the Framingham Heart Study (FHS). A total of 9253 participants had CRP measurements available at two examinations (PREVEND: 1997-1998 and 2001-2002; FHS Offspring cohort: 1995-1998 and 1998-2001). All CRP measurements were natural log-transformed before analyses. Cardiovascular disease included fatal and nonfatal cardiovascular, cerebrovascular and peripheral vascular events, and heart failure. Cancer included all malignancies except nonmelanoma skin cancers.ResultsThe mean age of the study population at baseline was 52.4±12.1 years and 51.2% (n=4733) were women. Advanced age, female sex, smoking, body mass index, and total cholesterol were associated with greater increases in CRP levels over time (Pall<.001 in the multivariable model). Baseline CRP, as well as increase in CRP over time (ΔCRP), were associated with incident CVD (hazard ratio [HR]: 1.29 per 1-SD increase; 95% confidence interval [CI]: 1.29 to 1.47, and HR per 1-SD increase: 1.19; 95% CI: 1.09 to 1.29 respectively). Similar findings were observed for incident cancer (baseline CRP, HR: 1.17; 95% CI: 1.09 to 1.26; ΔCRP, HR: 1.08; 95% CI: 1.01 to 1.15) and mortality (baseline CRP, HR: 1.29; 95% CI: 1.21 to 1.37; ΔCRP, HR: 1.10; 95% CI: 1.05 to 1.16).ConclusionInitial as well as subsequent increases in CRP levels predict future CVD, cancer, and mortality in the general population.Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

12 keywords...

hide…